PEN

As of 2026-09-11, PEN scores 38out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. PEN trades at $317.73, 117% above the band ceiling.

PEN scores 38 out of 100 on QNTM's five-factor model — a low-conviction reading — at 38 the factor profile is among the weaker names in the universe. Its strongest factor is sentiment at 54 (solid), where analyst and positioning signals are improving, followed by quality at 40. The weakest is value at 36, where valuation looks stretched. Among Healthcare stocks it sits in the lower 28% of Healthcare names by composite.

On valuation, PEN is priced near the top of its recent range — the rich end on the model's valuation read. The five factors sit close together, so the composite reflects a balanced profile rather than one dominant driver. The blended composite before the macro overlay was 39. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on PEN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where PEN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for PEN runs $124.50–$146.15. Current price $317.73 sits 117% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.